Skip to Content
scroll

Radiopharm Theranostics Ltd (RAD)

ASX.RAD $0.03

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

RAD $0.03

20 MINUTE DELAYED

TODAY

-7.14 %

1 YEAR RETURN

0.00%

VOLUME

832,680

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.02

0.05

ANALYSIS

i

PERFORMANCE

image description

i

SHARE PRICE ACTIVITY
Last (Price)

0.03

Change

0.00 (-7.14)

Bid / Ask

0.03 - 0.03

Volume

832,680

Turnover

21,954

Open

0.03

Day Range

0.03 - 0.03

VWAP

0.03

Prev Close

0.03

Last Trade

03/06 4:10pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

0

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00

PREVIOUS SECTION

ANNOUNCEMENTS

NEXT SECTION

RATIOS

image description

Business Summary

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology. The Company’s subsidiary includes Radiopharm Theranostics (USA) Inc. The Company has a pipeline of four licensed platform technologies, Nano-monoclonal antibodies (mAbs), Pivalate, AVβ6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, RAD201, RAD202, RAD204, RAD205, RAD207, RAD301, RAD302, RAD401 and RAD402.

image description

Relevant suggested news and content from the site

image description
Movers & Losers
image description
PULSE CHECK WEBINAR: Portfolio positioning towards FY26
image description
Tuesday 3rd June – ASX +29pts, IEL, 360, TWE
image description
IDP Education (IEL)
image description
Gerrish: The correction is done, we’re positioning for what comes next
image description
Tuesday 3rd June – Dow up +35pts, SPI up +69pts
image description
ASX200 Index
image description
Monday 2nd June – ASX -20pts, SOL, BKW & JHX
image description
ASX200 Index
image description
Monday 2nd June – Dow up +54pts, SPI up +8pts
image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top